Allart-Simon Ingrid, Moniot Aurélie, Bisi Nicolo, Ponce-Vargas Miguel, Audonnet Sandra, Laronze-Cochard Marie, Sapi Janos, Hénon Eric, Velard Frédéric, Gérard Stéphane
Université de Reims Champagne-Ardenne, Institut de Chimie Moléculaire de Reims (ICMR), UMR CNRS 7312, UFR Sciences, Moulin de la housse and UFR Pharmacie 51 rue Cognacq-Jay F-51096 Reims France
Université de Reims-Champagne-Ardenne, EA 4691 Biomatériaux & Inflammation en site OSseux (BIOS), UFR Pharmacie and UFR Odontologie 51 rue Cognacq-Jay F-51096 Reims France.
RSC Med Chem. 2021 Mar 1;12(4):584-592. doi: 10.1039/d0md00423e. eCollection 2021 Apr 28.
Cyclic nucleotide phosphodiesterase type 4 (PDE4), which controls the intracellular level of cyclic adenosine monophosphate (cAMP), has aroused scientific attention as a suitable target for anti-inflammatory therapy of respiratory diseases. This work describes the development and characterization of pyridazinone derivatives bearing an indole moiety as potential PDE4 inhibitors and their evaluation as anti-inflammatory agents. Among these derivatives, 4-(5-methoxy-1-indol-3-yl)-6-methylpyridazin-3(2)-one possesses promising activity, and selectivity towards PDE4B isoenzymes and is able to regulate potent pro-inflammatory cytokine and chemokine production by human primary macrophages.
4型环核苷酸磷酸二酯酶(PDE4)可控制细胞内环磷酸腺苷(cAMP)的水平,作为呼吸系统疾病抗炎治疗的合适靶点已引起科学界的关注。本文描述了带有吲哚部分的哒嗪酮衍生物作为潜在PDE4抑制剂的开发与特性,并将其作为抗炎剂进行了评估。在这些衍生物中,4-(5-甲氧基-1-吲哚-3-基)-6-甲基哒嗪-3(2)-酮具有良好的活性,对PDE4B同工酶具有选择性,并且能够调节人原代巨噬细胞中强效促炎细胞因子和趋化因子的产生。